Actively Recruiting
Advancing Troiluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study
Led by William Stoops · Updated on 2026-06-08
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
W
William Stoops
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of troriluzole, an investigational drug, on the influence of methamphetamine in people with methamphetamine use disorder. This human laboratory study is part of the Helping to End Addiction Long-term® (HEAL) Initiative, aiming to better understand how troriluzole might affect the reinforcing properties of methamphetamine in this population. Participants will be randomly assigned to one of three groups: daily oral placebo, daily oral troriluzole 140 mg, or daily oral troriluzole 280 mg. During experimental sessions, intravenous methamphetamine or placebo will be administered to assess the drug's effects while participants are admitted as inpatients for about one month. Participants will stay in the inpatient setting for approximately one month, during which they will undergo nine assessments of methamphetamine's reinforcing effects. Researchers will monitor health through medical and psychiatric evaluations, ECG readings, urine drug tests, and careful observation for any side effects. The study aims to gather detailed information about how troriluzole impacts methamphetamine use and related behaviors.
CONDITIONS
Brief Title
Methamphetamine and Troriluzole
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to speak and read English
- Not seeking treatment for drug use at the time of the study
- Female or male between 18 and 55 years old
- Recent methamphetamine use verified by positive urine test and DSM-5 diagnosis of methamphetamine use disorder
- Medically and psychiatrically healthy aside from methamphetamine use disorder (and opioid use disorder if co-morbid), as judged by study physicians
- ECG within normal limits as read by a cardiologist
- Females using effective birth control and not pregnant or breastfeeding
- No known contraindications or allergies to troriluzole
- For co-morbid methamphetamine and opioid use disorder group: recent opioid use verified by positive urine test and DSM-5 diagnosis of opioid use disorder with physiological dependence
You will not qualify if you...
- Unable to speak or read English
- Seeking treatment for drug use
- Under 18 or over 55 years old
- No recent methamphetamine use (negative urine test) and no DSM-5 diagnosis of methamphetamine use disorder
- Medically or psychiatrically unhealthy as judged by study physicians
- ECG outside normal limits as read by a cardiologist
- Females not using effective birth control or who are pregnant or breastfeeding
- Blood pressure higher than 140/90 mmHg on two consecutive screening visits
- Body mass index less than 18 or greater than 30; weight under 50 kg
- Taking any medications prescribed for a chronic condition
- Laboratory values more than three times normal at screening or during admission
- History of serious physical disease or diagnosis including seizure, diabetes, asthma, CNS tumors, or current/recent psychiatric disorders (other than methamphetamine use disorder or tobacco use disorder, and opioid use disorder if co-morbid) that would limit study compliance
- Contraindications or allergies to troriluzole such as hepatic disease (except asymptomatic HCV status cleared by physician)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits during screening
Duration - Approximately 1 month inpatient admission
Participants receive daily oral doses of placebo or troriluzole (140 mg or 280 mg) while undergoing experimental sessions with intravenous placebo and methamphetamine to study their effects.
9 experimental sessions during inpatient admission
Trial Site Locations
Total: 1 location
1
Psychopharmacology of Addiction Laboratory
Lexington, Kentucky, United States, 40507
Actively Recruiting
Research Team
W
William W Stoops, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here